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Abstract: The possibility of using human embryonic stem cells (ESC) for therapeutic purposes raises serious ethical objections, 
the most fundamental one being that until recently the only way to obtain ESC was with procedures that necessarily destroyed 
living human embryos. Due to this, research in this field has been rejected by many scientists, bioeticists, and has been 
banned by law in several countries. Efforts have been made to find procedures to obtain ESC without destroying embyros 
or putting them at risk. This paper reviews the scientific, technical and ethical aspects of the different strategies developed 
for this purpose. Embryo biopsy, ESC obtained from “dead” embryos, ESC produced by “parthenogenetic embryos”, ESC 
obtained by Altered Nuclear Transfer and induced pluripotent cells (iPSC) obtained by direct epigenetic reprogramming of 
somatic cells are the main five alternative reported in recent studies. 
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PROPUESTAS DE PRODUCCIÓN DE CÉLULAS MADRE EMBRIONARIAS SIN DESTRUIR 
EMBRIONES HUMANOS: RETOS CIENTÍFICOS Y BIOÉTICOS
Resumen: La posibilidad de usar células madre embrionarias humanas (ESC) para finalidades terapéuticas plantea 
graves objeciones éticas; la más fundamental es que, hasta hace poco, la única manera de obtener ESC era mediante 
procedimientos que destruían necesariamente embriones humanos vivos. Debido a esto, la investigación en este campo ha 
sido rechazada por muchos científicos, bioeticistas y ha sido prohibida por ley en varios países. Se han realizado esfuerzos 
para encontrar procedimientos que permitan obtener ESC sin destruir embriones o sin ponerlos en riesgo. En este 
documento examinamos los aspectos científicos, técnicos y éticos de las diferentes estrategias elaboradas para esta finalidad. 
La biopsia de embriones, ESC obtenidas de embriones “muertos”; ESC producidas por partenogénesis de embriones; 
ESC obtenidas mediante Transferencia Nuclear Alterada y células pluripotentes inducidas (iPSC), obtenidas mediante la 
reprogramación epigenética directa de las células somáticas, son las principales cinco opciones informadas en estudios recientes. 
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PROPOSTAS DE PRODUÇÃO DE CÉLULAS-TRONCO EMBRIONÁRIAS SEM DESTRUIR 
EMBRIÕES HUMANOS: DESAFIOS CIENTÍFICOS E BIOÉTICOS
Resumo: A possibilidade de se utilizar células-tronco embrionárias humanas (ESC) para finalidades terapêuticas apresenta 
graves objeções éticas, a mais fundamental é que, até recentemente, era a única maneira de obter ESC mediante procedimentos 
que destruíam necessariamente embriões humanos vivos. Devido a isso, a investigação neste campo tem sido recusada por 
muitos pesquisadores, bioeticistas e proibida por lei em vários paises. Esforços são realizados para encontrar procedimentos 
que permitam obter ESC sem destruir embriões ou colocá-los em risco. Neste documento examinamos os aspectos científicos, 
técnicos e éticos das diferentes estratégias elaboradas para esta finalidade. Biópsia de embriões, ESC obtidas de embriões 
“mortos”; ESC produzidas por partenogênese de embriões; ESC obtidas mediante Transferência Nuclear Alterada e células 
pluripotentes induzidas (iPSC), obtidas mediante a reprogramação epigenética direta das células somáticas, são as cinco 
principais opções informadas em estudos recentes.
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Introduction
Embryonic stem cells (ESC) have attracted scientific 
and public attention, mainly because of two issues. The 
first one is the promise of regenerative medicine through 
the replacement of damaged cells with new healthy cells, 
permitting the treatment and even cure of diseases, 
many of them without known effective treatments such 
as Parkinson’s disease, diabetes, osteoporosis, spinal cord 
injuries, Alzheimer’s disease, leukaemia and multiple 
sclerosis(1). The second one is an ethical issue(2). The 
main ethical objection is that ESC are obtained from 
human embryos, which implies their destruction. ESC 
can be obtained from surplus embryos resulting from 
in vitro fertilization (IVF) or from induced abortions. 
The production of cloned human embryos is another 
potential source for obtaining ESC. 
Stem cells can also be find in most tissues and organs of 
a developed animal and human organism and their rôle 
is to repair or to maintain the tissue in which are they 
found. They are called adult stem cells (ASC) or somatic 
stem cells, including those obtained from the umbilical 
cord. They have some general properties similar to ESC, 
as well as some differences that will be discussed later.
We will not address the ontological status of the human 
embryo and its right to life in this paper, although we 
are aware of the central rôle that this issue has in the 
debate. However, we can verify that the ethical debate 
exists and that for many people, governments and 
legislatures it is not acceptable to use human embryos 
for this or other purposes, given that it implies risks for 
the life, integrity and future of the embryos. In fact, this 
is why some countries have completely banned ESC 
research or have cut funding for such studies. It is in this 
context that different efforts have been made to obtain 
ESC with methods that do not imply risks for human 
embryos or their destruction. The objective of this paper 
is to analyse the scientific, technical and ethical aspects 
of these proposals.
What defines stem cells? Differences between 
ESC and ASC
There is no complete scientific consensus on the defi-
nition of stem cells, but there is agreement that stems 
cells have two essential and defining characteristics1: 
1 http://stemcells.nih.gov/info/basics/basics2.asp
 II. What are the unique properties of all stem cells?
They are undifferentiated cells that can be cultured •	
and will proliferate in vitro indefinitely, without 
differentiating. Thus a population of ESC can divi-
de in a laboratory and give rise to millions of cells. 
On the contrary, most ASC can divide in vitro for 
a more limited time. There is ongoing research to 
explain and overcome this limitation. 
In certain experimental environments ESC can •	
differentiate into different cells of body tissues and 
thus could be used for transplantation therapy in 
humans. It was thought that ASC could only diffe-
rentiate into cells of the tissues in which they exist, 
but current experimental data, while controversial, 
shows that ASC can differentiate into several cell 
types, including cells of the nervous system.
ESC produce a type of tumour called teratomas. •	
This is a property not yet found in ASC, and is 
one of the reasons not to begin clinical trials with 
ESC and research mainly restricted to animals. In 
contrast, there are many ongoing clinical trials 
with ASC(3)2. Bone marrow transplantation 
transplant for the treatment of cancers is a proven 
therapy(4).
The ethical limitations in obtaining human ESC •	
have encouraged efforts to obtain them with tech-
niques that would not provoke ethical objections, 
the most relevant of these is the destruction of 
human embryos. We will review propositions 
presented for this purpose, their technical feasi-
bility and the ethical and scientific controversies 
associated with them.
1. Embryo biopsy. One or more blastomeres are remo-
ved from a living embryo, as done in preimplantation 
genetic diagnosis (PGD) 
Technical feasibility. A group of scientists coordina-
ted by Robert Lanza from Advance Cell Technology 
published the first two papers reporting that ESC had 
been obtained by this method(5,6). Other researchers 
have obtained similar results(7).
Research with mouse embryo. Eight-cell stage mouse 
embryos were biopsied, using a single-cell embryo bi-
opsy technique, similar to the one used in pre-implan-
tation diagnosis of genetic defects(1). Under special 
culture conditions, cell lines were developed with the 
morphology and pluripotency marker characteristics 
of ESC. This was confirmed by the fact that these cell 
2 http://clinicaltrials.gov/ct2/results?term=adult+stem+cells 
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lines developed the three germ lines, and teratomas, 
and could produce chimeras when injected in mouse 
blastocysts. The blastomere-biopsied embryos were 
implanted and developed to term in a similar propor-
tion compared to control non-biopsied embryos. In a 
recent study, ESC lines were obtained from two cells, 
four- and eight-cell mouse embryo that proved to be 
more efficient1. 
Research in human embryo. Sixteen unused embryos 
produced by in vitro fertilization (IVF) were used for 
the research, with the informed consent of the “ow-
ners”. Multiple blastomere biopsies were performed 
from each embryo to reduce the number of embryos 
needed for the research. Some 91 blastomeres were 
obtained and cultured in a special medium. They devel-
oped 19 outgrowths of embryonic-like stem cells. From 
these, only two stable human ESC (hESC) cell lines 
proliferated for more than eight months, showing the 
morphology and expression of markers of pluripotency 
and the capacity to form tissues derived from the three 
embryonic germ layers and to form teratomas. These 
hES do not solve the problem of genetic compatibility. 
They could be stored in banks for use years later in 
case the biopsied embryo is allowed to continue its 
development and presents some of the diseases that 
could be treated with these ESC. 
Ethical considerations. This method raises different 
types of ethical objections: 
The technique implies the use of embryos produ-•	
ced by IVF, which raises ethical objections among 
many people. 
The fate of the biopsied embryo used for obtaining •	
human ESC. “Surplus” embryos from IVF are 
generally not implanted; they run the risk of being 
destroyed, as was the case in this study(8). 
Potential risks for the embryo without benefit. •	
The technique used is similar to that for preim-
plantation genetic diagnosis (PGD). In most cases, 
this is done to provide information in deciding 
about abortion, which is in itself a major ethical 
problem. The risks for the embryo to remove a 
blastomere are unknown, and the embryo receives 
no benefit with the procedure. For these reasons, 
the authors of the cited article do not recommend 
the procedure to be applied, except for PGD. 
There are also questions about the possibility of 
doing the PGD and the derivation of human ESC 
from only one blastomere. If two blastomeres are 
removed, the risk for the viability of the embryo 
increases(9). 
Risk of reprogramming a new embryo? Under the •	
conditions of this technique there is no theoretical 
or empirical evidence that this can happen. 
At this stage of knowledge, probably few parents would 
accept the risks of an embryo biopsy just to obtain 
ESC that could potentially benefit their child. And in 
the context of PGD there are still unsolved technical 
aspects. Embryo biopsy could reduce the probability of 
a successful IVF. With this method the number of ESC 
is very low, which could alter the accuracy of PGD. The 
results for the parents could finally be very few or no 
stem cell line and poorer cells for PGD(10).
2. ESC Obtained from “dead” embryos. 
Criteria for embryonic death: Technical feasibility. 
This alternative´s hypothesis seeks to apply similar 
criteria to the embryo as that of brain death used when 
transplanting organs from dead people. 
In 2004 Landry and Zucker proposed a definition •	
for embryo death applying the criteria of organ-
ismic death used in relation to brain death as the 
“irreversible loss of the capacity for all ongoing and 
integrated organic functioning”(11). They argued 
that embryo death is the loss of capacity of a 4- to 
8-cell human embryo for ongoing and integrated 
cellular division, growth and differentiation. They 
further argued that even if individual cells remain 
alive with the irreversible loss of these capacities 
the embryo could be properly considered or-
ganismically dead. How can this be objectively 
determined? The authors propose that death is 
equivalent to the “irreversible arrest of cleavage”. 
But they recognize the need for objective criteria 
to determine irreversible arrest. In 2006, they con-
tinued in their research to establish embryo death 
(12). In a retrospective study with 444 embryos, 
produced by IVF, that were considered nonviable, 
they found that 142 at day 5 had hypocellularity 
and lack of compaction. None of them progressed 
to compacted morula or normal blastocyst. The 
authors propose this criteria for assigning irrevers-
ible arrested development and hence “irreversible 
loss of integrated organic function”.
Zhang et al (2006) developed embryonic stem •	
cells from arrested embryos(13). 161 “surplus” 
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embryo produced by IVF were donated for the 
research. When no cleavage division of blasto-
meres was observed for 24 to 48 hours in the in 
vitro culture (IVC), the authors considered that an 
embryo was in a stage of irreversible arrest. Using 
this criterion with the 161 embryos, the results 
were the following:
- 29 developed normally until cells were extracted 
from IMC of the blastocyst.
- 119 arrested 3 to 5 days after fertilization: early 
arrested embryos
- 13 arrested 6 to 7 days after IVF: late arrested 
embryos
The authors tried to derive ESC from each of •	
these 3 groups: 
- ESC lines were derived from eight of the 29 
normally developing embryos.
- No ESC lines were derived from the early arres-
ted embryos (3-5-days) 
- One ESC line was obtained from one of 13 late 
arrested embryos (6-7 days) that seem to have 
the properties of normal ESC. 
The authors do not state explicitly that arrested •	
embryos are dead. They only point out that, as 
they are not viable, their use for obtaining ESC 
would produce fewer ethical objections.
Scientific and technical considerations. The central 
question about this approach is how to diagnosis an 
embryo as dead. The embryo must have at least part 
of the cells of its Internal Mass Cell (IMC) alive in an 
appropriate condition for deriving ESC. Brain death 
has very defined criteria, which cannot be applied to 
the embryo. Consequently, the analogy cannot be 
made. How can the loss of integration functions in 
the embryo be determined? There are at least two ques-
tions to resolve that have been pointed out by several 
scientists(14):    
Irreversible arrest is undoubtedly necessary for •	
determining that an embryo is dead, but: Is it 
sufficient? Is it equivalent to “irreversible loss of 
integrated organic function,” as stated by Landry 
and Zucker? The technique will continue to be 
compromised by the uncertainty as to what con-
stitute embryonic death. There are clear criteria 
for defining someone as irreversibly brain dead 
but no such clarity exists in the case of embry-
onic death. As Pearson notes the procedure is 
rendered unacceptable if there is even a remote 
possibility of reviving an embryo(14).
Second, even if the definition would be ac-•	
cepted, the question remains: are there reliable 
methods for determining when an embryo has 
arrived to a state of irreversible arrest? Landry 
and Zucker conclude from their retrospective 
study that the lack of compaction and hypo-
cellularity are sufficient criteria for defining 
irreversible arrest because none of the embryos 
with these characteristics progressed to com-
pacted morula or normal blastocyst. But this 
is an insufficient argument to affirm that the 
embryo is dead. The only logical conclusion is 
that these embryos are not viable. In a topic like 
this, retrospective studies have great limitations 
and prospective studies are limited by ethical 
considerations. 
The fact that the source is unused embryos from 
fertility treatments may encourage IVF embryo 
production. 
Scientific and ethical questions and objections: 
The quality of the ESC lines obtained from what are 
considered dead embryos is a matter of concern. In 
this respect, George Daley of the Harvard Stem Cell 
Institute wonders if cells from arrested embryos are 
not problematic, given that something provoked the 
arrest of embryo3.
From dead embryos to discarded embryos. 
The lack of a clear criteria for when to consider 
an embryo as dead has led to a redirecting of 
efforts to obtain ESC lines from embryos of 
poor quality that have attained the blastocyst 
stage. Lerou et al.(15) found that early arrested 
embryos (3 days) are very inefficient for obtain-
ing ESC lines, 0.6% (1/171), those arrested at 
day 5 4.1% (10/242) and those that reach the 
blastocyst stage, 8.5% (8/94). Based on these 
results, they verify that poor-quality embryos re-
jected for clinical use on day 5 post-fertilization 
have an efficiency for hESC drivation compa-
rable to that of frozen embryos. They add that 
there are potentially hundreds of thousands of 
embryos available for hESC derivation, given 
the enormous number of embryos discarded 
in the United States in assisted reproductive 
technology because the embryos are of low mor-
phological grade and have a low developmental 
3  Quoted by Antony Barnett and Robin McKie. The Observer, Sunday, 
September 24 2006. 
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potential. This is an expression of the slippery 
slope that begins with an imprecise definition 
of a dead embryo, continues with the use of 
embryos considered as not being viable, and 
finally of embryos of poor quality. It is clear 
that not all the poor quality embryos that are 
discarded are dead. 
3. ESC produced by “parthenogenetic 
embryos”
 What is parthenogenesis?•	  Parthenogenesis is 
the development of an embryo directly from 
an oocyte without fertilization. Many animals 
(such as fish, ants, flies, honey bees, amphibians, 
lizards and snakes) and plant species reproduce 
via parthenogenesis. Mammals are not capable of 
this type of reproduction. Mammalian embryonic 
development requires gene expression from the 
paternal genome. Parthenogenetic mouse embryos 
develop only to the early limb bud stage (16).
 Scientific and technical aspects. •	
- Development of mammalian parthenote to 
blastocyst stage. For a decade there have been 
efficient methods for producing parthenotes. 
The first method described in the literature con-
sists of arresting oocytes at the second meiotic 
metaphase (MII) and chemically activating 
them with cytochalasin, a drug that prevents 
extrusion of the second polar body(17). Diploid 
is maintained and the resulting pseudo zygote 
can develop into a blastocyst from which ESC 
can be isolated. Another method includes pre-
venting the extrusion of the first polar body. A 
tetraploid oocyte is formed that is transformed 
into a diploid with the extrusion of the second 
polar body(18). The two methods produce 
parthenote that result in a different type of 
genetic parthenotes. Different methods to 
develop parthenotes in mammals, including 
humans, have been developed in recent years 
(19). Even more recently, methods have been 
developed to produce parthenogenetic human 
blastocysts(20).
- Development of ESC from parthenogenetic 
blastocyst in animals. The first ESC lines 
from parthenotes were developed from mice in 
1983 (21). Subsequently, parthenogenetic ESC 
(pESC) lines have been developed from non-
human primates (22,23), rabbits (24,25) and 
mice (16,26). There is evidence that ESC are 
produced more efficiently from parthenogenetic 
embryos than from cloned embryos(27).
- Development of ESC from human parthe-
nogenetic blastocysts. Revazova et al repor-
ted the first pESC lines derived from human 
parthenotes(28,29). Their behaviour is similar 
to regular ESC in morphology and can give 
rise to the derivatives of the three germ layers 
in immune deficient mice. They have prolife-
rated for more than 10 months. These pESC 
would be compatible with the donor’s immune 
system. Other reports have also been recently 
published(30,31). It is interesting that the work 
reported by Hwang, that was once touted as the 
first to create human ESC lines through somatic 
cell nuclear transfer, has now been discovered to 
have originated by parthenogenesis(32).
Scientific and ethical questions. •	 Two major 
questions arise:
- Is a parthenote blastocyst an altered human em-
bryo or just a ball of cells without organization? 
This is a major anthropological question with 
significant ethical consequences. How to resolve 
this doubt seems difficult. Up to the develop-
ment of blastocyst, does this entity have the 
characteristics of an organism? It seems to have 
an integrated and organized functioning (self-
organization) and capacity for development and 
certain intrinsic autonomy (self-development) 
from the environment (33). Could it progress 
to other stages of development if implanted? 
In fact, parthenogenetic embryos have been 
implanted in different species and have reached a 
certain degree of development, although always 
abnormal (34,35). Are these abnormal embryos, 
or just a group of disorganized tissue? In this 
respect Kevin Fitzgerald argues that in mammals 
you cannot obtain parthenogenetic offspring. If 
a spontaneous parthenogenetic growth could 
occur it would not be an embryo. But if par-
thenogenetic embryos are artificially induced, 
there is a valid question about what is being 
produced4. The discussion continues and at the 
center is the question of the ontological status 
4 Barry P. Science News Online Week of Oct. 20, 2007; Vol. 172,
 No. 16.
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of parthenotes, which needs to be established 
before activated oocytes can be considered as an 
ethical source for pluripotent stem cells (36).
- Another ethical concern is how to obtain healthy 
eggs. In one study, as pointed out by one of the 
authors, J Janus, the oocytes were obtained from 
Russian women undergoing IVF procedures. No 
payments were made to the donors, but Janus 
states that the researchers did cover some costs 
of the IVF treatment”(37).
-  There is also the question of whether these 
pESC lines will be useful for regenerative 
medicine. What are the effects of not having 
parental imprinting? Brevini and Gandolfi 
(31) raise the question of the genetic stability 
and safety of such cells given that aneuploidy 
in human oocytes is relatively high. Concerns 
are expressed by other experts. Jeanne F. Lor-
ing4 has pointed out negative consequence can 
arise if the cell line is homozygous. She notes 
that in heterozygous cells the influence of either 
the paternal or maternal genes in determining 
whether a cell becomes cancerous is offset by the 
influence of the genes of the other parent. She is 
concerned that a gene copying error could result 
in a cell with two identical copies of the same 
gene, thus altering the balance of parental genes. 
This could in turn result in the cell becoming 
a malignant growth. This question needs more 
scientific research to be answered.
4. Altered Nuclear Transfer (ANT) and 
Oocyte Assisted Reprogramming (OAR).
 What is ANT-OAR?•	  William Hurlbut, a mem-
ber of the US President’s Council on Bioethics 
(PCBE), was the author of this proposal on 
December 2004. ANT consists of a modification 
of the technique of nuclear transfer with a pre-
emptive genetic and epigenetic modification of the 
nucleus of the somatic cell to be transferred(38). 
When there is also an alteration of the oocyte 
cytoplasm before transfer is done, the technique 
is termed ANT with OAR. We will first focus 
our analysis on ANT alone. The hypothesis of 
those who defend this line of research is that the 
technique will result in a biological entity without 
the characteristics of an organism. W. Hurlbut 
argues that these alterations prevent the potential 
for coordinated organization and developmental, 
which defines the embryonic organism. Thus, his 
method would allow for the generation of ESC 
lines using a biological entity that would not be 
considered an embryo(39). This is an hypothesis 
that must be empirically proved and philosophi-
cally analyzed. 
 •	 ANT: Scientific technical and ethical aspects. 
ANT was the initial proposition. The proponents 
of this technique argue that the Cdx2 gene is 
indispensable for the constitution of an embryo. 
This gene would be essential for the integration 
of the new organism as a whole. If the gene is 
silenced there is no organism, but rather only a 
biological entity lacking of self-organization and 
development. From an empirical point of view 
there are 2 main objections to this statement. The 
research that concluded that the Cdx2 gene was 
expressed very early in embryonic development 
(40) and that it was present in the first cleavage 
in only one of the blastomeres was retracted (41). 
Other studies have demonstrated that the Cdx2 
gene is not expressed at the two stage blastomeres 
in mice(42). Thus, this gene might not be essential 
for the first stages of development. 
 There is one published paper in which ESC lines 
were obtained with this strategy in mice. The 
technique consisted of silencing the Cdx2 gene 
from the nucleus of the somatic cell transferred 
to the oocyte(43). The cloned blastocysts were 
morphologically abnormal with no expression 
of the CDx2 gene. They lacked a functional tro-
phoblast and failed to implant in foster mothers. 
Nonetheless, ESC lines were derived from these 
blastocysts. To test their pluripotency they were 
injected into diploid blastocysts. Postnatal chimeras 
were generated. The injected Cdx2 deficient ESC 
lines contributed to the formation of most tissues 
in the chimeras, with the exception of the intesti-
ne, where all the cells were Cdx2 positive derived 
from the host blastocyst. It is known that the Cdx2 
gene is necessary for the development of the gastro 
intestinal tract(44).
 It is relevant that Meissner and Jaenisch, authors 
of this article(43), recognize that the ethical dile-
mma may not be resolved since the Cdx2-deficient 
embryo appears to be normal in the first stages of 
development before the Cdx2 gene is expressed. 
 Another aspect is that the function of the Cdx2 
gene could be restored in the ESC derived by this 
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technique. In theory, the so-called biological en-
tity by its defenders could be transformed into an 
embryo during the development to blastocyst by 
restoring the capability of the Cdx2 at the stage of 
2 or 4 cells. After recuperating the status of being 
an embryo, it could be possible to transform again 
the embryo into a biological entity by silencing the 
Cdx2 gene. It seems unlikely that the ontological 
condition of a biological organism could depend 
only on the simple silencing and activating of a 
gene. Thus, we could have new human beings that 
appear and disappears with this action alone. This 
demonstrates that the ethical aspects have not been 
solved and that the facts show that what are being 
produced are disabled embryos and not biological 
entities. 
 The philosophical debate has centered on what are 
sufficient and necessary characteristics of a new or-
ganism5? How can we differentiate a biological en-
tity from an organism? Scientists and philosophers 
with the same anthropology regarding the human 
embryo differ in their evaluation of this technique 
(45-47). Although an in-depth discussion of the 
different positions is beyond the objectives of this 
article, we agree with the view stated above that the 
silencing of the Cdx gene does not clearly produce 
something that is not an embryo.
ANT with OAR.•	  Scientific, technical and ethi-
cal aspects. A group of thirty-five scientists, 
moral philosophers and theologians sign a joint 
statement supporting this alternative(48). The 
hypothesis of the ANT modification is that a 
combination of epigenetic alterations of both the 
somatic nucleus and the enucleated egg would 
directly produce a pluripotent cell “that from the 
beginning would be clearly and unambiguously 
distinct from, and incompatible with, those of 
an embryo”(48). W Hurlbut, the father of the 
proposal, argues that ANT-OAR results in a cell 
that at no point has the potential for integrated 
organization and coordinated development and 
behaves directly like pluripotent cell6.
 The ethical debate has been similar to that around 
ANT alone. In our opinion, much of the ethical 
discussion remains theoretical given that there is 
5 Communio 2004 and 2005 N° 31 and 32. Critiques of Altered Nuclear 
Transfer (ANT) and Oocyte Assisted reprogramming (OAR)
6 Hurlbut W. 2007 http://www.alterednucleartransfer.com/publica-
tions/1.pdf
no empirical data that this technique (ANT-OAR) 
is feasible. There is a debate as to whether this is 
a sound scientific hypothesis (49). We think that 
until animal research arrives to some concrete 
results, it is difficult to make scientific and ethical 
conclusion. 
5. Direct epigenetic reprogramming of 
somatic cells to induce pluripotent cells 
(iPSC)
 Development of epigenetic reprogramming of •	
somatic cells. The capacity of the oocyte to dedi-
fferentiate somatic cells in the process of cloning 
resetting them to their embryonic epigenetic state 
was a major discovery in biology that is still not 
well understood(50). Somatic cells can also be 
reprogrammed to a pluripotency state by fusion 
with ESC(51,52). These facts led to the hypothe-
sis that certain factors present in the ESC could 
induce epigenetic reprogramming of somatic cells 
to produce embryonic stem cells without using an 
egg. 
 In 2006 Takahashi and Yamanaka published a 
seminal paper on nuclear reprogramming research 
demonstrating that this was possible (53). They 
hypothesized that factors that play a crucial role 
in maintaining pluripotency in ESC could also 
induce pluripotency if introduced to somatic cells. 
They first selected 24 genes as candidates for this 
purpose. These genes are expressed in ESC and are 
responsible for their unique characteristics. The 
genes were introduced by retroviral transduction 
into mice skin cells (fibroblasts). The fibroblasts 
had been previously modified by the introduction 
of a Neomycin resistant gene in the Fbx15 gene 
by homologous recombination. The Fbx15 gene, 
although it is not essential for maintaining pluri-
potency, is activated in ESC. Thus, cell colonies 
in which the Fbx15 gene activated will not be 
destroyed in the presence of Neomycin, and this 
serves in selecting colonies that resemble ESC. In 
their first experiments with the introduction of the 
24 genes, Takahashi and Yamanaka obtained a small 
percentage of drug-resistant colonies. These cells 
were similar to ESC in morphology, growth and 
markers of pluripotency. Nanog was demethylated 
but not Oct4. No drug resistant colonies were 
obtained when only one gene was introduced.
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Through several sequential experiments to determine 
which genes were essential for this reprogramming 
process, Takahashi and Yamanaka identified 4 genes 
which, when injected into skin fibroblasts, were more 
efficient in producing what they called induced plu-
ripotent stem cells (iPSC). These cells demonstrated 
some of the typical characteristics of ESC: pluripotency 
markers, capacity to form teratomas and to produce 
fetal chimeras when injected in a mouse blastocyst. 
The researchers were surprised that the NANOG 
gene, known for its importance in maintaining pluri-
potency, was not one of the essential genes to produce 
iPSC. With the reprogramming process through the 
transduction of the four genes, the NANOG gene 
and some other endogenous genes involved in the 
pluripotent state of the cells were expressed, but not 
the endogenous Oct4 gene. This demonstrates that the 
introduction of the genes produces a vast modification 
of the transcription state of the cells. Although the cells 
had similar characteristics to ESC they were different 
in some aspects: There was some dissimilarity in gene 
expression and none of the fetal chimeras produced 
with these cells developed into an adult mouse. The 
epigenetic reprogramming was done first with mouse 
embryonic fibroblasts and then with adult mouse 
fibroblasts obtained from the tail-tip. 
Confirmation and advances in the epigenetic •	
reprogramming of somatic cells to iPSC
Since the publication of Takahashi and Yamanaka 
an impressive amount of research has been done up 
to the present. In June-July 2007, three papers were 
published reporting the production of iPSC by epi-
genetic reprogramming(54-56). These investigations 
made some modifications in the technique, especially 
in the selection strategy. They not only confirmed the 
discovery made by Takahashi and Yamanaka, but also 
resolved some of the problems pointed out by them, 
such as the activation of the Oct4 endogenous gene, 
the generation of viable chimeras and the confirmation 
that the maintenance of the pluripotent state of the 
cells was mainly due to the activation of endogenous 
pluripotency genes such as Oct4, Sox2 and Nanog. 
Soon afterwards, Meissner et al. (57) managed to select 
the iPSC by morphology without genetically modifying 
the fibroblasts, as was done in previous experiments. 
The use of genetically unmodified fibroblast donors 
eliminates a possibly harmful factor for the future use 
of iPSC in humans. To monitor the reprogramming 
process, they introduced an enhanced green fluorescent 
protein (GFP) marker in the Oct4 locus. 
An important step forward was the production of iPSC 
without introducing the oncogene c-Myc(58,59). It has 
been reported that the c-Myc gene can be reactivated 
in animal chimeras derived from iPSC. 
The epigenetic process has also been successful with 
other somatic cells in mouse. Induced pluripotent stem 
cells have been generated from adult liver cells(60), 
from mature B lymphocytes(61), and from pancreatic 
βeta(62). In some cases, efficiency was lower(59) and 
in others there was less tumor formation(58).
Differentiation of iPSC into different types of cells 
had been proven in vivo (generation of teratomas and 
chimeras) but not in vitro. In vitro differentiation of 
mouse iPSC into cells of the cardiovascular and hae-
matopoietic lineages were then achieved (63). These 
results are promising advances in developing compa-
tible haematopoietic and cardiovascular regenerative 
therapies in humans. 
Potential of iPSC for treating diseases in •	
animals.
The therapeutic potential of iPSC has been tested for 
the first time in two recent studies. The first paper 
reports the correction of a mouse model with huma-
nized sickle cell anaemia, treated with transplantation 
of haematopoietic progenitors obtained in vitro from 
autologous iPSC(64). 
A second investigation managed to obtain functional 
neural cells from mouse iPSC (65). After producing 
a model of Parkinson’s disease in a group of rats, one 
group was treated with the neural cells derived from 
iPSC and another group served as control. An improve-
ment in the symptoms of the treated rats was observed 
in comparison to the control group.
Production of iPSC from human somatic •	
cells. 
Takahashi, Yamanaka (2007) and their team reprodu-
ced their original work in reprogramming mouse fibro-
blast with the reprogramming of human skin, synovial 
and newborn fibroblasts(66). They used the same 
four factors, Oct4, Sox2, Klf4 and c-Myc, introduced 
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to the fibroblast by retroviral infection. The authors 
concluded that their study opened the way to generate 
pluripotent stem cells that are specific to patients and 
diseases eliminating the risk of rejection. They argued 
that despite retroviral integration, human iPSC could 
contribute to understanding disease mechanisms and 
have applications in drug screening and toxicology. 
A second article published simultaneously achieved 
similar results, although in this case researchers used a 
different combination of transcription factors: Oct4, 
Sox2, Nanog and Lin28(67). Two other studies from 
different researchers have also obtained iESC from hu-
man somatic cells with similar results as the previous 
first studies(68,69). 
Differentiation of human iPSC is an essential step for 
their use in therapies. Dimos et al. reported the genera-
tion of human iPSC from fibroblasts of a patient with 
amyotrophic lateral sclerosis (ALS). Using a similar 
protocol for the differentiation of ESC, they success-
fully managed to differentiate in vitro the iPSC into 
motor neurons of the type destroyed in ALS(70). 
Park et al have derived human iPSC from a wide range 
of genetic diseases(71). This is an important advance 
for the in vitro study of normal and pathologic devel-
opment, allowing for a better understanding of the 
diseases and possible treatments. 
Scientific and ethical considerations•	
The impressive advances obtained in the reprogram-
ming of somatic cells to a pluripotent state that seems 
to be identical to ESC may imply a major scientific 
breakthrough and the achievement of ethical consensus 
regarding the research and the future of regenerative 
medicine for complex and currently incurable diseases. 
However, there are still many scientific and technical 
aspects to overcome before it is ethically acceptable to 
begin clinical trials 
Researchers are aware that there are some major diffi-
culties to surmount before using reprogrammed cells 
for therapeutic applications in human beings. Some 
impediments have been surmounted: the c-myc, a 
known oncogene used in the first experiments has 
proven to be dispensable for direct reprogramming of 
somatic cells(56,57), and the use of transgenic donors 
(modified fibroblasts) is not crucial for the selection 
of the iPSC colonies(55). But there are still major 
concerns
- The first is the potentially harmful effects in-
volved in the use of retroviral vector for intro-
ducing ectopic genes. Researchers are seeking 
alternatives that could accomplish the repro-
gramming of somatic cells while circumventing 
the introduction of genes. This is probably the 
most important challenge that investigators are 
trying to overcome.
- The second is the low efficiency of the method.
- Thirdly, there is the production of teratomas. 
iPSC, as ESC, can produce teratomas when 
implanted under the skin. Before advancing 
to therapeutic applications, it will be necessary 
to clearly demonstrate that differentiated iPSC 
cells do not produce tumors in hosts. Despite 
the production of iPSC without c-myc gene, 
the entire problem has not been resolved.
- Finally there is the challenge to progress in the 
generation of human iPSC and the need to 
develop consistent differentiation procedures 
to allow its use in regenerative medicine.
From an ethical perspective, the reprogramming of 
somatic cells to obtain iPSC bypasses the major prob-
lems involved in obtaining and using ESC. There is no 
destruction or manipulation of the embryo, nor the need 
for oocytes. Its potential in the treatment of a host of 
diseases in different areas of medicine offers the possibil-
ity of consensus for the first time between scientists and 
ethicists with different anthropological and ethical views. 
The cloning of human embryos for obtaining ESC com-
patible with patients for treating diseases, independent 
of the ethical problems involved, has less of a future than 
epigenetic reprogramming. It is relevant that Ian Wilmut 
on Novembrer 2007 decided to abandon his research 
into human cloning and switched to research in the line 
of reprogramming somatic cells to iPSC. His decision 
was not motivated primarily by ethical considerations so 
much as for practical and scientific reasons (72)7. Other 
scientists think that with the advances in this technique, 
the so-called human therapeutic cloning will most likely 
be left behind (73). 
For all those who recognize a human being in the hu-
man embryo, with the dignity and rights of a member 
of the human family, this is a major line of research that 
merits significant support and work. But one should be 
cautious in creating too much expectation of a prompt 
7  Telegraph Interview to Ian Wilmut, Novembrer 2007.
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application in regenerative medicine in humans. The 
technical and scientific problems pointed out above 
must be overcome.
Conclusions
The different approaches described in this paper to 
obtain pluripotent cells without destroying or using 
human embryos have been discussed from a scientific 
and ethical viewpoint. We think that the advances in 
obtaining human iPSC by direct epigenetic reprogram-
ming is the most promising strategy for obtaining 
pluripotent cells without using embryos or eggs, and 
thus represent the closest convergence of science and 
ethics. 
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